Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors
Current Oncology · 2026
DOI: 10.3390/curroncol33050240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2026. Verfasst von Olexiy Aseyev und 6 weiteren Autor:innen. Beteiligte Einrichtung: Regional Cancer Centre, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
It is well-known that immune checkpoint inhibitors (ICIs) can lead to uncommon but potentially life-threatening immune-related adverse events (irAEs) such as checkpoint-inhibitor pneumonitis (CIP). Early recognition, identification, and treatment are crucial with regard to decreasing toxicity from ICIs. However, there is a discrepancy in the incidence rates between the clinical trials and postmarketing studies. Several postmarketing studies have developed early detection methods and identified new risk factors in developing CIP. Thus, in this narrative review, we aim to review these incidence rates, early detection methods, and clinical risk factors for CIP in NSCLC patients, which could help to improve CIP diagnosis and management for enhanced NSCLC care. Major clinical trials and postmarketing studies of CIP incidence, early detection methods, and risk factors in NSCLC were reviewed. A wide array of potential risk factors has been implicated in the development of CIP in NSCLC, such as having preexisting interstitial lung disease, receiving PD-1 inhibitors, receiving combination ICI therapy instead of ICI monotherapy, lower pretreatment hemoglobin and albumin levels, increased baseline plasma IL-8 levels, and impaired baseline pulmonary function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Cancer Centre, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada.
- Division of Clinical Sciences, Northern Ontario School of Medicine University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada.
- Polyclinic Department, Universal Clinic "Oberig", 3 Zoolohichna Street, 03057 Kyiv, Ukraine.
- Internal Medicine, Northern Ontario School of Medicine University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada.
- Clinical Research Services, Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada.
- Michael G. DeGroote School of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada.
ORCID-Profile: Olexiy Aseyev, Minghan Shi, Rabail Siddiqui
Zitieren
APA
Aseyev, O., Zrielykh, L., Shi, M., Filipovic, K., Seymour, C., Siddiqui, R., & Biman, B. (2026). Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors. Current Oncology. https://doi.org/10.3390/curroncol33050240
Vancouver
Aseyev O, Zrielykh L, Shi M, Filipovic K, Seymour C, Siddiqui R, et al. Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors. Current Oncology. 2026. doi:10.3390/curroncol33050240
BibTeX
@article{Aseyev2026,
author = {Aseyev, Olexiy and Zrielykh, Liliia and Shi, Minghan and Filipovic, Katherine and Seymour, Claire and Siddiqui, Rabail and Biman, Birubi},
title = {Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33050240}
}
EUVIMED